Literature DB >> 16427437

Magnesium sulfate: role as possible attenuating factor in vasospasm morbidity.

Daniel Monte-Serrat Prevedello1, Joacir Graciolli Cordeiro, Andrei Leite de Morais, Nestor Saucedo Saucedo, Iara B Chen, João Cândido Araújo.   

Abstract

BACKGROUND: Among the many complications of SAH, one of the most important is vasospasm. Several treatment alternatives have been proposed for this condition, with far-from-ideal results being obtained. Magnesium sulfate recently returned to the scene (with still unproven benefit) as an adjuvant in the treatment of vasospasm.
METHODS: Seventy-two patients diagnosed with SAH by aneurysm rupture were submitted to microsurgery craniotomy and subdivided in 2 groups. Group 1, formed by 48 patients, received prophylactic hypervolemic and hemodilution therapy in addition to nimodipine. Group 2, composed of 24 patients, received the same treatment of group 1 with the addition of magnesium sulfate in continuous infusion from 120 to 150 mg a day, keeping serum magnesium levels close to double normal values.
RESULTS: Age was 49 +/- 12.6 years. Ratio of female to male was 3.16:1. Most patients were admitted in a Hunt-Hess grade 2 (46.4%) and Fisher grade 3 (52.8%). Anterior communicating artery aneurysms were the most common in location (38.8%). Both groups were compared, and there was no statistical difference related to age, sex, and Glasgow, Fisher, or Hunt-Hess admission grades. No statistical difference in vasospasm incidence was found between the two groups. However, in group 1, vasospasm was correlated with a longer hospitalization time (P = .0003), different from group 2, in which patients with vasospasm receiving magnesium sulfate required less hospitalization time.
CONCLUSION: Magnesium did not seem to interfere in vasospasm frequency but apparently acted favorably in decreasing morbidity and length of hospital stay.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16427437     DOI: 10.1016/j.surneu.2005.11.035

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  11 in total

1.  Effect of magnesium sulfate therapy on patients with aneurysmal subarachnoid hemorrhage using serum S100B protein as a prognostic marker.

Authors:  Tamer Hassan; Mahmoud Nassar; Sherif Mohammed Elhadi; Wafa Kamel Radi
Journal:  Neurosurg Rev       Date:  2011-12-15       Impact factor: 3.042

2.  Super-selective intra-arterial magnesium sulfate in combination with nicardipine for the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage.

Authors:  Qaisar A Shah; Muhammad Zeeshan Memon; M Fareed K Suri; Gustavo J Rodriguez; Osman S Kozak; Robert A Taylor; Ramachandra P Tummala; Gabriela Vazquez; Alexandros L Georgiadis; Adnan I Qureshi
Journal:  Neurocrit Care       Date:  2009-04-16       Impact factor: 3.210

Review 3.  Calcium antagonists for aneurysmal subarachnoid haemorrhage.

Authors:  S M Dorhout Mees; G J E Rinkel; V L Feigin; A Algra; W M van den Bergh; M Vermeulen; J van Gijn
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18

4.  Cerebral vasospasm pharmacological treatment: an update.

Authors:  Ioannis Siasios; Eftychia Z Kapsalaki; Kostas N Fountas
Journal:  Neurol Res Int       Date:  2013-01-31

5.  Magnesium treatment for neuroprotection in ischemic diseases of the brain.

Authors:  Thomas Westermaier; Christian Stetter; Ekkehard Kunze; Nadine Willner; Furat Raslan; Giles H Vince; Ralf-Ingo Ernestus
Journal:  Exp Transl Stroke Med       Date:  2013-04-25

Review 6.  Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage: an updated systemic review and meta-analysis.

Authors:  George K C Wong; Ronald Boet; Wai S Poon; Matthew T V Chan; Tony Gin; Stephanie C P Ng; Benny C Y Zee
Journal:  Crit Care       Date:  2011-02-07       Impact factor: 9.097

7.  Magnesium Protects in Episodes of Critical Perfusion after Aneurysmal SAH.

Authors:  Ekkehard Kunze; Nadine Lilla; Christian Stetter; Ralf-Ingo Ernestus; Thomas Westermaier
Journal:  Transl Neurosci       Date:  2018-09-01       Impact factor: 1.757

8.  Magnesium Levels and Diastolic Blood Pressure (DBP) as a Vasospasm Prediction Metric in Patients With Aneurysmal Subarachnoid Hemorrhage (SAH).

Authors:  Paras Savla; Maxwell A Marino; Dario A Marotta; James Brazdzionis; Saman Farr; Stacey Podkovik; James Wiginton; Emilio C Tayag; Vladimir Cortez; Dan E Miulli
Journal:  Cureus       Date:  2022-03-14

Review 9.  Economic and Humanistic Burden of Cerebral Vasospasm and Its Related Complications after Aneurysmal Subarachnoid Hemorrhage: A Systematic Literature Review.

Authors:  Juliette C Thompson; François-Xavier Chalet; Eric J Manalastas; Neil Hawkins; Grammati Sarri; Darren A Talbot
Journal:  Neurol Ther       Date:  2022-04-20

Review 10.  Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage.

Authors:  Salah G Keyrouz; Michael N Diringer
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.